Yumanity Therapeutics Inc (YMTX)

NASDAQ
9.76
-0.04(-0.41%)
  • Volume:
    19,829
  • Bid/Ask:
    9.60/9.90
  • Day's Range:
    9.75 - 9.76

YMTX Overview

Prev. Close
9.8
Day's Range
9.75-9.76
Revenue
10.43M
Open
9.93
52 wk Range
8.24-36.8
EPS
-18.64
Volume
19,829
Market Cap
99.98M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
97,306
P/E Ratio
-
Beta
0.69
1-Year Change
-66.67%
Shares Outstanding
10,202,506
Next Earnings Date
Aug 11, 2021
What is your sentiment on Yumanity Therapeutics Inc?
or
Vote to see community's results!

Yumanity Therapeutics Inc News

Yumanity Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralBuySellBuy
Technical IndicatorsSellNeutralStrong BuyNeutralSell
SummaryNeutralNeutralStrong BuyNeutralNeutral

Yumanity Therapeutics Inc Company Profile

Yumanity Therapeutics Inc Company Profile

Employees
47

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer’s diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson’s disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.

Read More
  • Buy Gnpx instead of this ***big big future for Gnpx
    0
    • Woow 🥱
      0
      • Reverse Stock Split. Don't buy this.Dont. Buy. This.Just going to plummet back to sub $1
        0
        • You are wrong. Yumanity is a strong company. We will see
          0
      • 😵😵what happend here !!!!!
        0
        • 20:1 reverse split. So nothing happened really.
          0
      • 20 old shares = 1 share now.
        0
        • This is crazy!!!
          0
          • what happen why took 1000%
            0
          • Reverse Stock Split. The app is not smart enough to tell the difference between an actual price rise qnd a rise casued by a massive reduction in shares outstanding.
            0
          • In other words, avoid it like its on fire. All it will do is plummet.
            0
        • Any new?
          0
          • We still expecting more upside here?
            1
            • big jump ahead.hold tight
              0
              • $2 and up
                0
                • 1.23 by the end!
                  2
                  • -60%. OUCH!!!
                    0
                    • sold at my target 4.00 and will re-enter at .090 cent if touchs
                      0
                  • might be a Head and shoulder pattern
                    0
                    • Bingo :)
                      0
                      • Well done, been in for a while, more by happenstance rather than knowledge and conviction, like yourself. ; )
                        0
                    • Check below when i said at .70 cent this will hit 4.00 ;)
                      0
                      • @Bman pti 3.10 :)
                        0
                        • why is it worth to buy?
                          0
                          • Because it go upppp....
                            0
                        • why is it worth to buy?
                          0
                          • Coz of the upcoming data of clinical trial
                            0
                        • It took longer than i thought but here we go - the road to 4.00
                          0
                          • Mmm, this seems like a better $4 play than natural gas lol
                            0
                        • Any positive news coming soon for this company?
                          0
                          • Nope
                            0
                        • This company is done. RIP.
                          5
                          • Buy now target is 4.00 in weeks glta :)
                            0
                            • Hey Moe, any reasoning behind 4.00? Thank you!
                              0
                            • Ya reason behind it is he is in buy position
                              0
                            • This drop was because The triplet therapy failed to demonstrate a significant treatment benefit at day 14 as determined by a measure of lung function . The company says it plans to evaluate optimal doses of in longer duration studies in CF patients "who are not predisposed to rapid pulmonary decline." The trials should wind up by year-end with preliminary data available thereafter. It plans to launch three new 28-day Phase 2 trials in CF patients with at least one F508del mutation this year for the triplet therapy and 801/808 combo therapies. It maintains its expectation that Phase 3 development will launch. I did buy because i believe gap will be filled in few weeks - it may take longer but this company in the long run will be back to 20.00 watch and see time will tell glta :)
                              0
                          • Does anyone know why it went down so much today
                            0
                            • definitely $22 on the way
                              0
                              • comon, you can do it
                                0
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.